- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04150198
MECHANISMS OF NEURONAL RESILIENCE IN ALZHEIMER'S DISEASE AND ITS FOCAL VARIANTS: A PET/MR STUDY (PET-AL)
Study Overview
Status
Intervention / Treatment
Detailed Description
Working hypotheses We hypothesize that "focal" patients (PCA) versus "diffuse" patients (AD-Y) have (i) less severe white matter involvement; (ii) effective reorganization of the functional brain networks; iii) pathologically, a different topography and lesion load.
This project has no redundancy with the work already done in our team and in other teams at the international level.
Expected benefits This study will highlight the neural mechanisms underlying resiliency in a group of AD patients who, although having the same disease, present with a very different clinical and cognitive profile. Demonstration of these specific mechanisms of resilience in the diseased brain is essential to better understand the pathophysiological processes of AD. We consider that the pharmacological approach and the functional reeducation to this disease depend essentially on a better knowledge of both the topographic distribution of the underlying histopathology (in particular, the tau protein), and the response capacity from the brain to these lesions (state of connection of networks, functional reorganization). In addition, when treatments for AD are available, a precise definition of phenotypic variants will be essential for the selection of patients for these therapies and for therapeutic follow-up. In the longer term, resilient neural circuits could be modulated and strengthened through transcranial stimulation. Indeed, promising results have been obtained showing that these techniques can improve the performance of altered cognitive functions in patients with dementia.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Marie Odile Habert, MCU-PH
- Phone Number: 01 57 27 40 00
- Email: marie-odile.habert@aphp.fr
Study Contact Backup
- Name: Raffaella Migliaccio, MD, PhD, HDR
- Phone Number: 01 57 27 40 00
- Email: raffaella.migliaccio@inserm.fr
Study Locations
-
-
-
Orsay, France, 91401 cedex
- Service Hospitalier Frédéric Joliot SHFJ
-
Contact:
- Vincent Pr LEBON
- Phone Number: 01.69.86.77.01
- Email: vincent.lebon@universite-paris-saclay.fr
-
Contact:
- Michel Dr BOTTLAENDER
- Phone Number: 01.69.86.77.12
- Email: michel.bottlaender@cea.fr
-
Paris, France, 75013
- Service de Médecine Nucléaire - Hopital La Pitié Salpetriere
-
Contact:
- Marie Odile, MCU-PH
- Email: marie-odile.habert@aphp.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
For all subjects:
- Affiliation to a social security insurance or beneficiary
- Informed consent form signed by the participant or his / her legal representative
- Participants aged 40 to 80 years.
Selection of AD-Y group
- In vivo proof of Alzheimer's pathology:
- Determination of specific proteins on the cerebrospinal fluid (CSF, a routine care procedure). The values considered pathological (AD) are Aβ1-42 peptide <500 (μg / ml), and / or tau protein> 450 and phosphorylated tau protein> 60, IATI index <1, tau / Aβ protein ratios > 1.23 as well as phosphorylated tau protein / Aβ1-42> 0.211.
- And / or a positive PET-amyloid imaging test.
- Early-onset episodic memory deficit (<65 years), progressive onset with evidence of hippocampal amnesic syndrome at neuropsychological assessment.
In memory tests, the amnesic hippocampal syndrome is defined by: a deficit of the free recall despite a reinforced encoding, an effectiveness of the indexing or an impairment of the recognition capabilities, the presence of intrusions. The presence during the tests of false memories spontaneous (intrusions) or provoked (false recognitions) is also very contributive to the definition of amnesic syndrome of the hippocampal type.
PCA group selection
Patients with a clinical and cognitive profile suggestive of PCA, characterized by:
- an in vivo proof of the Alzheimer pathology (see selection of the AD-Y group)
- a specific impairment of neuro-visual abilities, in the absence of major disorders of episodic memory (hippocampal) and executive functions.
Two possible variants:
- occipito-temporal variant: visuo-perceptive deficit in the foreground, early onset and progressive worsening; lack of visual identification of objects, symbols, words or faces;
- biparietal variant: visuospatial deficit in the foreground, early settlement and progressive worsening; Gerstmann syndrome; Balint syndrome; gestural apraxia; visual-spatial neglect.
Selection of the control subjects group
- Normal neurological and neuropsychological examinations.
- Control subjects will be matched in age to patients.
Non-inclusion Criteria:
General non-inclusion criteria:
- Medical history of torsade de pointe or risk of torsade de pointes
- Patient treated with drugs known to lengthen QT (see www.crediblemeds.org)
- Contraindication to radiopharmaceutical injection:
For precautions of safety of use of the radiopharmaceutical, a blood sample allowing to check the renal and hepatic functions will be realized before imagery. The delay between the sampling and the neuroimaging visit is left to the investigator's discretion based on the patient's biological results. In particular, the glomerular filtration rate will be calculated from the results obtained.
In the event of renal insufficiency (GFR 30mL / min / 1.73m2), hepatic insufficiency or any other biological anomaly of grade 3 or higher detected during these analyzes, the participant will not be able to carry out PET imaging. In this case, the results of the analyzes will be sent to the doctor indicated by the participant. This evaluation, which involves a determination of serum creatinine, is part of the standard routine biological assessment performed in the context of cognitive disorders
Inability to provide informed consent by participant or legal representative:
- Patient deprived of liberty by decision of justice or not benefiting from social cover.
- Person in the process of participating in another therapeutic research or in a period of exclusion from another research.
- Participants with a contraindication to MRI: pacemaker or cardiac defibrillator, implanted equipment activated by an electrical, magnetic or mechanical system, haemostatic clips of intracerebral aneurysms or carotid arteries , carriers of orthopedic implants.
- Contraindication to radiopharmaceutical injection: known hypersensitivity to the active substance or to any of the excipients, renal impairment (GFR 30mL / min / 1.73m2), hepatic insufficiency or any other biological abnormality of grade 3 or higher
- Person suffering from claustrophobia.
- Pregnancy (for women of childbearing age, a urine pregnancy test will be performed on the day of the inclusion visit and the PET-MRI examination).
- Any symptoms or biological values suggestive of a systemic disorder (renal, hepatic, cardiovascular, pulmonary) or any other medical conditions that could interfere with the interpretation of test results or compromise the health of patients.
- Person subject to a legal safeguard.
Specific non-inclusion criteria for AD-Y and PCA patients:
- Sudden appearance of cognitive deficits.
- Gait disturbances, convulsions, major behavior modification.
- Focal alterations to neurological examination, extrapyramidal signs, hallucinations, fluctuations. cognitive.
- Psychiatric, cerebrovascular, metabolic, inflammatory pathology.
Specific non-inclusion criteria for control subjects:
- Pathological neurological examination
- History of neurological disease (in particular ischemic stroke or neurodegenerative disease) or psychiatric illness (particularly severe depression, psychosis, or bipolar illness still requiring drug treatment at the time of inclusion)
- Physical affection that is serious or can interfere with cognitive functions.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Patients with Alzheimer (<65 years) (AD-Y)
15 patients with a diagnostic of MA-J
|
All participants will have a PET / MRI examination including: i) a 30-minute PET scan, 80 minutes after intravenous injection of 240 MBq of 18F-AV1451 ± 10% ii) a ZTE sequence (for attenuation correction of PET images), a 3D T1 anatomical sequence, a diffusion MRI, a functional MRI at rest (total duration: 45 minutes).
These acquisitions will be made during the same exam session on a hybrid PET / MRI camera allowing simultaneous acquisitions.
This visit lasts about 3 hours.
|
Experimental: Patients with posterior Cortical Atrophy (PCA)
15 patients with a diagnostic of PCA
|
All participants will have a PET / MRI examination including: i) a 30-minute PET scan, 80 minutes after intravenous injection of 240 MBq of 18F-AV1451 ± 10% ii) a ZTE sequence (for attenuation correction of PET images), a 3D T1 anatomical sequence, a diffusion MRI, a functional MRI at rest (total duration: 45 minutes).
These acquisitions will be made during the same exam session on a hybrid PET / MRI camera allowing simultaneous acquisitions.
This visit lasts about 3 hours.
|
Active Comparator: Control
15 controls
|
All participants will have a PET / MRI examination including: i) a 30-minute PET scan, 80 minutes after intravenous injection of 240 MBq of 18F-AV1451 ± 10% ii) a ZTE sequence (for attenuation correction of PET images), a 3D T1 anatomical sequence, a diffusion MRI, a functional MRI at rest (total duration: 45 minutes).
These acquisitions will be made during the same exam session on a hybrid PET / MRI camera allowing simultaneous acquisitions.
This visit lasts about 3 hours.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
highlight of the "resilient" neural networks
Time Frame: up to 3 months
|
For this, we will study: 1) The topographic distribution regions of tau lesions, thanks to PET brain imaging using the 18F-AV-1451 as a ligand. |
up to 3 months
|
quantify the impairment (ie brain vulnerability) in AD-Y and in PCA
Time Frame: up to 3 months
|
For this, we will study: 2) The correlation between the distribution of these tau lesions and: the cortical volume, the indices of integrity of the white matter bundles, the functional neural networks, as well as the reorganization of the "hubs" of these networks, thanks to the structural MRI, diffusion (MRI) and functional at rest (fMRI) imaging.2) |
up to 3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
correlation between the concentration of tau-tauphosphorylated protein in cerebrospinal fluid (CSF) with the lesion load measured in PET
Time Frame: up to 3 months
|
this comparison is a key element of characterization of this new ligand compared to widely validated CSF biomarkers
|
up to 3 months
|
predictive model of functional alterations based on the structural alterations of the gray matter and the white matter.
Time Frame: up to 3 months
|
To establish this correlation the evaluation criterion is represented by the measurement of cortical thickness, the indices of integrity of the beams of the white substance (fractional anisotropy, average, radial and perpendicular diffusivities), as well as the integration values of the functional networks and the distribution of "hubs"
|
up to 3 months
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- C19-40
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer Disease, Early Onset
-
Alnylam PharmaceuticalsRecruitingEarly-Onset Alzheimer DiseaseUnited Kingdom, United States, Netherlands, Canada
-
Mayo ClinicRecruitingEarly Onset Alzheimer DiseaseUnited States
-
ProgenaBiomeRecruitingAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States
-
ElMindA LtdUnknownDepression | Aging | Mild Cognitive Impairment | Early Onset Alzheimer DiseaseUnited States
-
University of MiamiColumbia University; National Institute on Aging (NIA); Case Western Reserve... and other collaboratorsRecruitingDementia | Mild Cognitive Impairment | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Dementia of Alzheimer TypeUnited States
-
Massachusetts Institute of TechnologyRecruitingAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Alzheimer'sUnited States
-
Cognito Therapeutics, Inc.RecruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
Cairo UniversityNot yet recruitingEarly Disease Onset
-
Swiss Federal Institute of TechnologyAlzheimer's Drug Discovery FoundationRecruiting
Clinical Trials on TEP/IRM
-
Ramsay Générale de SantéDr Arnaud DevèzeCompletedHearing Implants | Implant Hearing ArtefactFrance
-
Institut National de la Santé Et de la Recherche...CompletedTourette SyndromeFrance
-
Institut National de la Santé Et de la Recherche...Institut National de Recherche en Informatique et en AutomatiqueNot yet recruitingTBI (Traumatic Brain Injury)France
-
Sofia Med HospitalActive, not recruiting
-
University Hospital, Strasbourg, FranceUnknown
-
University Hospital, Strasbourg, FranceUnknown
-
Stefania La Grutta, MDCompleted
-
VA Office of Research and DevelopmentCompleted
-
Medical Park Gaziantep HospitalMuğla Sıtkı Koçman University; Bahçeşehir UniversityCompletedRecurrence | Hernia, Inguinal | Hernia, Femoral | Inguinal Hernia, Indirect | Inguinal Hernia, Direct | Neuralgia, Atypical | Neuralgia, Ilioinguinal | Neuralgia, Iliohypogastric NerveTurkey